Global Heparin Market Size By Type(Low Molecular Weight Heparin, Ultra-low Molecular Weight Heparin), By Application(Venous Thromboembolism, Atrial Fibrillation, Renal Impairment), By Geographic Scope and Forecast

Heparin Market Size And Forecast

Heparin Market size was valued at USD 9.47 Billion in 2022 and is projected to reach USD 12.71 Billion by 2030, growing at a CAGR of 3.75% from 2024 to 2030.

The global heparin market is influenced by a range of factors, including the prevalence of conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE), the aging of the global population, and the increasing demand for heparin in emerging markets. Other factors that may impact the heparin market include regulatory changes, patent expirations, and competition from alternative anticoagulant drugs. Overall, the heparin market is expected to continue to grow in the coming years as the demand for anticoagulant therapies increases. However, some potential risks and challenges could impact the market, such as the ongoing COVID-19 pandemic and concerns about the safety and efficacy of heparin products.

Global Heparin Market Definition

Heparin is a type of anticoagulant medication that is commonly used in the prevention and treatment of blood clots. Heparin is a common anticoagulant injection that is often referred to as ordinary heparin or unfractionated heparin (UFH). Hep-Lock is one of the brand names for heparin. It works by inhibiting the formation of blood clots in the body and is typically administered via injection. Heparin is commonly used in a variety of medical settings, including hospitals, clinics, and in-home care. In individuals with particular medical problems or who are undergoing medical procedures that raise the risk of blood clot development, such as surgery, heparin is a drug that prevents blood clots from forming. Heparin injection is an anticoagulant. It is used to lessen blood’s capacity to clot and to assist keep dangerous clots from forming in blood arteries.

Global Heparin Market Overview

The Heparin Market is expanding mostly because of the rising incidence of blood clotting problems, while other factors such as heparin’s adverse effects could slow this expansion

The rising frequency of chronic diseases is one of the major reasons driving the heparin market. Chronic illnesses including cardiovascular disease, kidney disease, and inflammatory ailments are becoming more common. The biggest risk factors for these chronic illnesses are being overweight, not exercising regularly, eating poorly, drinking excessively, and smoking. In the US, extreme obesity is predicted to affect 25% of the population by 2030. The prevalence of cardiovascular disorders, including deep vein thrombosis and pulmonary embolism, has increased as a result of the rise in obesity and other conditions. These conditions are symptoms of venous thromboembolism. The CDC estimates that 900,000 people in the United States could experience venous thromboembolism each year.

Also, there is a sharp rise in the occurrence of several coagulation disorders worldwide, including Von Willebrand disease, hemophilia, deep vein thrombosis, hypercoagulable states, and clotting factor deficiencies. For instance, the CDC reported that roughly 400 newborns were born with hemophilia in July 2020. Annually in the US. Moreover, the CDC reported in February 2020 that DVT/PE, also known as venous thromboembolism, affects nearly 900,000 people annually in the US. Many coagulation problems are becoming more common among people worldwide, necessitating ongoing monitoring to plan for more medical procedures. In turn, this is fueling the expansion of the world heparin market. Furthermore, during big procedures, doctors advise coagulation tests.

The limited availability of raw materials from China for the production of products based on porcine is one of the major restraints on the expansion of the worldwide market. For example, in July 2020, according to a representative of China’s agriculture ministry, China’s efforts to control African swine flu remained challenging as more than 11 outbreaks were reported along with the presence of new variants. African swine fever (ASF), a fatal disease for swine, has led to the widespread culling of pigs to control outbreaks. The latest outbreaks were noted in China’s northern provinces.The second factor limiting market growth is the higher prices associated with LMWH, which could prevent its wider acceptance in developing economies and is predicted to do so in the ensuing years.

Global Heparin Market Segmentation Analysis

The Global Heparin Market is segmented based on Type, Application, And Geography.

Heparin Market By Type

• Low Molecular Weight Heparin
• Ultra-low Molecular Weight Heparin
• Unfractionated Heparin

The LMWH market segment dominated the worldwide heparin market. The high rate of product acceptance in developed markets and the superior safety profiles of these goods compared to competing ones account for the segment’s dominance. Fragmin (Dalteparin sodium), Lovenox (Enoxaparin sodium), and Innohep are a few crucial LMWH medications (Tinzaparin sodium). Several industry participants are also concentrating on the creation and introduction of fresh LMWH goods on the international market. For instance, Valeo Pharma Inc. reported in November 2019 that it had submitted a New Drug Submission for an LMWH biosimilar, which Health Canada has accepted for assessment.

Heparin Market By Application

• Venous Thromboembolism
• Atrial Fibrillation
• Renal Impairment
• Coronary Artery Disease
• Others

The global heparin market can be segmented based on its application. Heparin is a commonly used anticoagulant, and its primary application is in the prevention and treatment of blood clots. Therefore, one of the key segments of the heparin market is the treatment of thrombosis and related disorders. This includes deep vein thrombosis (DVT), pulmonary embolism (PE), and other venous thromboembolism (VTE) conditions. Another key application of heparin is in hemodialysis, where it is used to prevent clotting in the dialysis machine and tubing during the treatment. In addition, heparin is also used in other medical procedures, such as heart surgeries and angioplasty, where it is used to prevent clotting and reduce the risk of heart attacks and strokes. Heparin also has applications in the cosmetic industry, where it is used as an anti-aging agent in some skincare products. It is believed that heparin has a beneficial effect on the skin, helping to reduce wrinkles and other signs of aging.

Heparin Market by Geography

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• Latin America

North American region will have the lion’s share of the global market. Due to the region’s high prevalence of cardiovascular diseases including pulmonary embolism, higher adoption of cutting-edge goods, high healthcare spending, and the existence of important market players active in the sales of these products, North America dominates the global market. For instance, the Centers for Disease Control and Prevention (CDC) projected in October 2022 that every year, 805,000 people in the United States experience a heart attack, of which 605,000 were newly reported instances.Due to the region’s high acceptance of technologically advanced goods and the rising prevalence of a variety of cardiovascular disorders, the market in Europe is predicted to be the second-largest market in the world. For instance, according to a report released by the British government in February 2022, venous thrombosis affects roughly 1 in 1,000 persons in the UK each year.

Key Players

The major players in the market are; Pfizer Inc., Leo Pharma A/S, Dr.Reddy’s Laboratories Ltd, GlaxoSmithKline plc, Techdow USA Inc, Sanofi, Optimvia Pharmaceuticals, Aspen Holdings, Fresenius SE & Co. KGaA, B Braun Medical Inc., Sandoz, Gland Pharma among others. This section provides a company overview, ranking analysis, company regional and industry footprint, and ACE Matrix.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

Key Developments

• In February 2022, Heparin Sodium Injection was introduced on the market in the United States by Techdow USA Inc.
• In January 2022, Optimvia Pharmaceuticals, an Ohio-based biotechnology business, asserted to have created a synthetic process for producing huge quantities of heparin, which is required to generate a common blood thinner, at a competitive price.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.